Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Essential Hypertension
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Co-administration of AD-227A and AD-227B | Experimental | AD-227A + AD-227B + Placebo of AD-227C |
|
| AD-227A | Active Comparator | AD-227A + Placebo of AD-227B + Placebo of AD-227C |
|
| Co-administration of AD-227A and AD-227C | Active Comparator | AD-227A + Placebo of AD-227B + AD-227C |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AD-227A | Drug | Per Oral, 1 Tablet, Once a day for 8 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in MSSBP | Change from Baseline in Mean Sitting Systolic Blood Pressure | Baseline to Week8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| JeongEun Park | Contact | +82-31-891-6989 | parkje@addpharma.co.kr |
| Name | Affiliation | Role |
|---|---|---|
| Chong-Jin Kim | Gangnam CHA Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gangnam CHA Medical Center | Recruiting | Seoul | South Korea |
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| AD-227B | Drug | Per Oral, 1 Tablet, Once a day for 8 weeks |
|
| AD-227C | Drug | Per Oral, 1 Tablet, Once a day for 8 weeks |
|
| Placebo of AD-227B | Drug | Per Oral, 1 Tablet, Once a day for 8 weeks |
|
| Placebo of AD-227C | Drug | Per Oral, 1 Tablet, Once a day for 8 weeks |
|